CardioVentures holds an indirect controlling interest in an Indian limited liability company (“SSI India“). SSI-India is engaged in the development, commercialization, manufacture and sale of medical and surgical robotic systems utilizing patents, trademarks and other intellectual property. It has received full clinical approval from Indian regulators and is now ready to take and ship orders for its Mantra robotic surgical system
Upon completion of the merger, the company will change its name to
It empowers physicians and surgical practices through the use of software and artificial intelligence.
AVRA focuses its research and development efforts on meeting the increasing expectations of patients and physicians for the precision, efficiency and safety offered by robotics, artificial intelligence and proprietary software combined with proven medical devices and surgical instruments.
For more information, visit AVRA’s website at www.avramedical.com.
This press release may contain statements that are not historical facts and are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate”, “assume”, “believe”, “estimate”, “expect”, “will”, “intend”, “may”, “plan”, “project”, “should”, “could”, “aim,” “designed,” “potential,” “forecast,” “goal,” “goal,” “goal,” or the negative of such terms, or other similar expressions to identify such forward-looking statements. These statements relate to future events or AVRA’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievements to differ materially from future results, level of activity or performance or achievements expressed or implied by these forward-looking statements.
Contact: [email protected]
2022 GlobeNewswire, Inc., Source